Slideshows Images Quizzes

Copyright © 2018 by RxList Inc. RxList does not provide medical advice, diagnosis or treatment. See additional information.

Erleada

Last reviewed on RxList: 7/24/2020
Erleada Side Effects Center

Last reviewed on RxList 9/25/2019

Erleada (apalutamide tablets) is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer. Common side effects of Erleada include:

The dose of Erleada is 240 mg (four 60 mg tablets) administered orally once daily. Swallow tablets whole. Erleada can be taken with or without food. Erleada may interact with medications that are sensitive substrates of CYP3A4, CYP2C19, CYP2C9, UGT, P-gp, BCRP, or OATP1B1. Tell your doctor all medications and supplements you use. Erleada is not indicated for use in females, so it is unlikely to be used during pregnancy or while breastfeeding. Males with female partners of reproductive potential should talk to their doctors about using contraception during treatment and for 3 months following the last dose of Erleada.

Our Erleada (apalutamide tablets) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

SLIDESHOW

Screening Tests Every Man Should Have See Slideshow
Erleada Professional Information

SIDE EFFECTS

The following are discussed in more detail in other sections of the labeling:

Clinical Trial Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

SPARTAN, a randomized (2:1), double-blind, placebo-controlled, multi-center clinical study, enrolled patients who had non-metastatic, castration-resistant prostate cancer (NM-CRPC). In this study, patients received either ERLEADA at a dose of 240 mg daily or a placebo. All patients in the SPARTAN study received a concomitant gonadotropin-releasing hormone (GnRH) analog or had a bilateral orchiectomy. The median duration of exposure was 16.9 months (range: 0.1 to 42 months) in patients who received ERLEADA and 11.2 months (range: 0.1 to 37 months) in patients who received placebo.

Overall, 8 patients (1%) who were treated with ERLEADA died from adverse reactions. The reasons for death were infection (n=4), myocardial infarction (n=3), and cerebral hemorrhage (n=1). One patient (0.3%) treated with placebo died from an adverse reaction of cardiopulmonary arrest (n=1). ERLEADA was discontinued due to adverse reactions in 11% of patients, most commonly from rash (3%). Adverse reactions leading to dose interruption or reduction of ERLEADA occurred in 33% of patients; the most common (>1%) were rash, diarrhea, fatigue, nausea, vomiting, hypertension, and hematuria. Serious adverse reactions occurred in 25% of ERLEADA-treated patients and 23% in patients receiving placebo. The most common serious adverse reactions (>2%) were fracture (3%) in the ERLEADA arm and urinary retention (4%) in the placebo arm.

Table 1 shows adverse reactions occurring in ≥10% on the ERLEADA arm in SPARTAN that occurred with a 2% absolute increase in frequency compared to placebo. Table 2 shows laboratory abnormalities that occurred in ≥15% of patients, and more frequently (>5%) in the ERLEADA arm compared to placebo.

Table 1: Adverse Reactions in SPARTAN

System/Organ Class ERLEADA
N=803
Placebo
N=398
All Grades Grade 3-4 All Grades Grade 3-4
Adverse reaction % % % %
General disorders and administration site conditions
  Fatigue1,4 39 1 28 0.3
Musculoskeletal and connective tissue disorders
  Arthralgia4 16 0 8 0
Skin and subcutaneous tissue disorders
  Rash2 24 5 6 0.3
Metabolism and nutrition disorders
  Decreased appetite5 12 0.1 9 0
  Peripheral edema6 11 0 9 0
Injury, poisoning and procedural complications
  Fall4 16 2 9 0.8
  Fracture3 12 3 7 0.8
Investigations
  Weight decreased4 16 1 6 0.3
Vascular disorders
  Hypertension 25 14 20 12
  Hot flush 14 0 9 0
Gastrointestinal disorders
  Diarrhea 20 1 15 0.5
  Nausea 18 0 16 0
1 Includes fatigue and asthenia
2 Includes rash, rash maculo-papular, rash generalized, urticaria, rash pruritic, rash macular, conjunctivitis, erythema multiforme, rash papular, skin exfoliation, genital rash, rash erythematous, stomatitis, drug eruption, mouth ulceration, rash pustular, blister, papule, pemphigoid, skin erosion, and rash vesicular
3 Includes rib fracture, lumbar vertebral fracture, spinal compression fracture, spinal fracture, foot fracture, hip fracture, humerus fracture, thoracic vertebral fracture, upper limb fracture, fractured sacrum, hand fracture, pubis fracture, acetabulum fracture, ankle fracture, compression fracture, costal cartilage fracture, facial bones fracture, lower limb fracture, osteoporotic fracture, wrist fracture, avulsion fracture, fibula fracture, fractured coccyx, pelvic fracture, radius fracture, sternal fracture, stress fracture, traumatic fracture, cervical vertebral fracture, femoral neck fracture, and tibia fracture
4 Grade 4 definitions do not exist for these reactions
5 Includes appetite disorder, decreased appetite, early satiety, and hypophagia
6 Includes peripheral edema, generalized edema, edema, edema genital, penile edema, peripheral swelling, scrotal edema, lymphedema, swelling, and localized edema

Additional clinically significant adverse reactions occurring in 2% or more of patients treated with ERLEADA included hypothyroidism (8.1% versus 2% on placebo), pruritus (6.2% versus 2% on placebo), ischemic heart disease (3.7% versus 2% on placebo), and heart failure (2.2% versus 1% on placebo).

Table 2: Laboratory Abnormalities Occurring in ≥ 15% of ERLEADA-Treated Patients and at a Higher Incidence than Placebo (Between Arm Difference > 5% All Grades) in SPARTAN

Laboratory Abnormality ERLEADA
N=803
Placebo
N=398
All Grades Grade 3-4 All Grades Grade 3-4
% % % %
Hematology
  Anemia 70 0.4 64 0.5
  Leukopenia 4747 0.3 2929 0
  Lymphopenia 4141 2 2121 2
Chemistry
  Hypercholesterolemia1 7676 0.1 4646 0
  Hyperglycemia1 70 2 59 1
  Hypertriglyceridemia1 6767 2 4949 0.8
  Hyperkalemia 3232 2 2222 0.5
1 Does not reflect fasting values

Rash

In SPARTAN, rash associated with ERLEADA was most commonly described as macular or maculo-papular. Adverse reactions of rash were reported for 24% of patients treated with ERLEADA versus 6% of patients treated with placebo. Grade 3 rashes (defined as covering > 30% body surface area [BSA]) were reported with ERLEADA treatment (5%) versus placebo (0.3%).

The onset of rash occurred at a median of 82 days of ERLEADA treatment. Rash resolved in 81% of patients within a median of 60 days (range: 2 to 709 days) from onset of rash. Four (4%) of patients treated with ERLEADA received systemic corticosteroids for treatment of rash. Rash recurred in approximately half of patients who were re-challenged with ERLEADA.

Hypothyroidism

Hypothyroidism was reported for 8% of patients treated with ERLEADA and 2% of patients treated with placebo based on assessments of thyroid-stimulating hormone (TSH) every 4 months. Elevated TSH occurred in 25% of patients treated with ERLEADA and 7% of patients treated with placebo. The median onset was Day 113. There were no Grade 3 or 4 adverse reactions. Thyroid replacement therapy was initiated in 7% of patients treated with ERLEADA. Thyroid replacement therapy, when clinically indicated, should be initiated or dose-adjusted [see DRUG INTERACTIONS].

Read the entire FDA prescribing information for Erleada (Apalutamide Tablets)

IMAGES

See Images
Related Resources for Erleada

Related Drugs

© Erleada Patient Information is supplied by Cerner Multum, Inc. and Erleada Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors

CONTINUE SCROLLING FOR RELATED SLIDESHOW